"
Autoantibodies to GFAP (glial fibrillary acidic protein) and to dopamine in patients with acute and chronic cerebrovascular disоrders"
written by P.R. Kamchatnov, A.V. Chugunov, N.Yu. Ruleva, S.F. Dugin, D.A. Basse, B.A. Abusueva, L.I. Buriachkovskaya, E.I. Gusev,
published by
Health,
Vol.2 No.12, 2010
has been cited by the following article(s):
|
[1]
|
Serum brain damage biomarkers as a diagnostic and prognostic tool in ischemic stroke
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova,
2023
DOI:10.17116/jnevro202312308237
|
|
|
|
|
[2]
|
Role of neuron-specific enolase, glial fibrillar acidic protein and NR2-antibodies in early diagnostic of ischemic stroke
Translational Medicine,
2021
DOI:10.18705/2311-4495-2021-8-5-5-20
|
|
|
|
|
[3]
|
Stroke Biomarkers
Neuromethods,
2020
DOI:10.1007/978-1-4939-9682-7_4
|
|
|
|
|
[4]
|
New diagnostic and prognostic biomarkers of the ischemic brain damage
Translational Medicine,
2020
DOI:10.18705/2311-4495-2020-7-5-29-42
|
|
|
|
|
[5]
|
THE POSSIBILITY OF USING GLIAL FIBRILLARY ACIDIC PROTEIN AS A BIOMARKER IN THE ACUTE PERIOD OF STROKE
Russian neurological journal,
2019
DOI:10.30629/2658-7947-2019-24-4-4-15
|
|
|
|
|
[6]
|
Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker
Trends in Neurosciences,
2015
DOI:10.1016/j.tins.2015.04.003
|
|
|
|